Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Multitarget HD-tDCS and Spatial Navigation Memory in Schizophrenia (HD-tDCS-SCZ)

tiistai 10. marraskuuta 2026 päivittänyt: School of Psychology, Northwest Normal University

Effects of Multitarget High-Definition Transcranial Direct Current Stimulation and Learning Strategy on Spatial Navigation Memory in Patients With Schizophrenia: A Randomized Sham-Controlled Study

This study investigated whether multitarget high-definition transcranial direct current stimulation (HD-tDCS), combined with cognitive learning strategies, could improve temporal order memory during spatial navigation in patients with schizophrenia.

Schizophrenia is frequently associated with cognitive impairments, including difficulties remembering the order of events and navigating unfamiliar environments. This study examined whether noninvasive electrical brain stimulation could enhance the benefits of repeated memory testing compared with repeated studying.

In this randomized, single-blind, sham-controlled study, 59 hospitalized patients with schizophrenia were assigned to receive either active or sham HD-tDCS while completing a spatial navigation learning task. Both groups performed forward-testing and restudy conditions. Active stimulation was delivered for 20 minutes, and spatial navigation learning lasted approximately 45 minutes.

Spatial navigation memory was evaluated using landmark-order recall accuracy. Resting-state functional near-infrared spectroscopy (fNIRS) was performed before and after the intervention to examine changes in functional connectivity between prefrontal and parietal brain regions.

The study aimed to determine whether multitarget HD-tDCS could improve spatial navigation memory, enhance the benefits of forward testing, and influence functional connectivity in brain networks involved in cognitive control and spatial attention.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

  1. Background and Rationale:

    Cognitive impairment is a core feature of schizophrenia and contributes to difficulties in daily functioning. Temporal order memory, which refers to the ability to remember the sequence of events, plays an important role in spatial navigation and the organization of everyday experiences. Patients with schizophrenia frequently demonstrate impairments in temporal processing, episodic memory, and spatial navigation.

    The dorsolateral prefrontal cortex (DLPFC) and inferior parietal lobule (IPL) are involved in cognitive control, working memory, spatial attention, and contextual updating. Altered functional interactions between these regions may contribute to cognitive difficulties in schizophrenia.

    High-definition transcranial direct current stimulation (HD-tDCS) is a noninvasive brain stimulation technique that can modulate cortical activity. Multitarget HD-tDCS may influence multiple cortical regions involved in distributed cognitive networks. Combining brain stimulation with cognitive strategies may provide an approach to improving memory performance.

    Forward testing is a learning strategy in which previously studied information is tested before subsequent information is learned. This strategy may facilitate new learning by reducing interference and improving contextual differentiation. The present study investigated whether multitarget HD-tDCS could enhance the effects of forward testing on spatial navigation memory.

  2. Study Design

    This study used a randomized, single-blind, sham-controlled, parallel-group design. Sixty hospitalized patients diagnosed with schizophrenia according to DSM-5 criteria were assigned to either an active HD-tDCS group or a sham stimulation group, with 30 participants allocated to each group.

    Both groups completed the same spatial navigation learning task, including forward-testing and restudy conditions.

  3. Intervention:

    Multitarget HD-tDCS was administered using a Starstim 32 stimulation system (Neuroelectrics, Spain). Stimulation was directed toward dorsolateral prefrontal and parietal cortical regions.

    Participants in the active stimulation group received 2.0 mA stimulation for 20 minutes while performing the spatial navigation learning task. Participants in the sham group underwent the same electrode setup but received only brief current stimulation periods at the beginning and end of the session.

  4. Spatial Navigation Task:

    Participants completed a spatial navigation task involving four routes presented in video format. The task included two learning strategies.

    In the forward-testing condition, participants completed interim memory tests after studying route information. In the restudy condition, participants repeatedly studied route information without equivalent interim testing.

    Route materials and presentation order were counterbalanced across conditions. Spatial navigation performance was assessed using landmark-order recall accuracy during the final route test.

  5. Neuroimaging Assessment:

    Resting-state functional near-infrared spectroscopy (fNIRS) was used to investigate changes in cortical functional connectivity associated with the intervention.

    Eight-minute resting-state fNIRS recordings were obtained before and after the spatial navigation task. The recordings measured changes in oxygenated and deoxygenated hemoglobin concentrations.

    Functional connectivity was estimated between regions associated with the DLPFC and IPL. Changes in functional connectivity were examined to explore potential relationships between brain network activity and spatial navigation performance.

  6. Study Objectives:

The study investigated whether multitarget HD-tDCS combined with cognitive learning strategies could influence immediate temporal order memory during spatial navigation in patients with schizophrenia.

Additional objectives included examining intervention-related changes in resting-state frontoparietal functional connectivity and exploring associations between connectivity measures, cognitive performance, and clinical characteristics.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

60

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

    • Gansu
      • Lanzhou, Gansu, Kiina
        • The Third People's Hospital of Lanzhou

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

17 vuotta - 62 vuotta (Lapsi, Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Duration of illness of at least 1 year.

Predominantly negative symptoms based on clinical assessment.

Total Positive and Negative Syndrome Scale (PANSS) score greater than 70.

Stable antipsychotic medication for at least 8 weeks.

Montreal Cognitive Assessment (MoCA) score between 10 and 26.

Exclusion Criteria:

  • Substance abuse, excluding caffeine and tobacco use.

Presence of other psychiatric disorders.

Contraindications to transcranial electrical stimulation, including intracranial implants or a history of epilepsy.

Pregnancy or breastfeeding.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Active Multitarget HD-tDCS

Participants received active multitarget high-definition transcranial direct current stimulation (HD-tDCS) at 2.0 mA for 20 minutes while completing spatial navigation learning tasks involving forward-testing and restudy conditions.

Multitarget high-definition transcranial direct current stimulation was administered using a Starstim 32 system (Neuroelectrics, Spain). Active stimulation was delivered at 2.0 mA for 20 minutes, concurrently with spatial navigation learning tasks. Stimulation targeted dorsolateral prefrontal and parietal cortical regions.

Huijausvertailija: Sham HD-tDCS

Participants received sham HD-tDCS using the same electrode montage as the active group, with brief current delivery and approximately 30-second ramping periods at the beginning and end of stimulation, without sustained stimulation. Participants completed the same spatial navigation learning tasks involving forward-testing and restudy conditions.

Sham stimulation was administered using the same Starstim 32 system and electrode montage as the active-stimulation condition. Brief current application, including approximately 30-second ramping periods at the beginning and end of the session, was used without sustained stimulation. Participants performed the same spatial navigation learning tasks as those in the active-stimulation group.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Landmark-Order Recall Accuracy
Aikaikkuna: Immediately following the spatial navigation learning task (approximately 45 minutes after task initiation).

Landmark-order recall accuracy was assessed during the final test of the spatial navigation task under forward-testing and restudy learning conditions. Accuracy was calculated as the proportion of correctly recalled landmark-order information, with scores ranging from 0 to 1. Higher scores indicate better temporal order memory performance.

Immediately following the spatial navigation learning task (approximately 45 minutes after task initiation).

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in Resting-State DLPFC-IPL Functional Connectivity (HbO)
Aikaikkuna: Baseline and immediately after the intervention (8-minute resting-state recordings at each assessment).

Resting-state functional connectivity between dorsolateral prefrontal cortex (DLPFC)-associated and inferior parietal lobule (IPL)-associated regions was assessed using functional near-infrared spectroscopy (fNIRS). Pearson correlation coefficients between predefined regions of interest were Fisher z-transformed and averaged. The outcome was calculated as post-intervention minus pre-intervention connectivity using oxygenated hemoglobin (HbO) signals.

Baseline and immediately after the intervention (8-minute resting-state recordings at each assessment).
Change in Resting-State DLPFC-IPL Functional Connectivity (HbR)
Aikaikkuna: Baseline and immediately after the intervention (8-minute resting-state recordings at each assessment).

Resting-state functional connectivity between dorsolateral prefrontal cortex (DLPFC)-associated and inferior parietal lobule (IPL)-associated regions was assessed using functional near-infrared spectroscopy (fNIRS). Pearson correlation coefficients between predefined regions of interest were Fisher z-transformed and averaged. The outcome was calculated as post-intervention minus pre-intervention connectivity using deoxygenated hemoglobin (HbR) signals.

Baseline and immediately after the intervention (8-minute resting-state recordings at each assessment).

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Päätutkija: Wenxi Su, PhD, School of Psychology, Northwest Normal University

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 9. tammikuuta 2026

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 20. toukokuuta 2026

Opintojen valmistuminen (Todellinen)

Sunnuntai 31. toukokuuta 2026

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 10. marraskuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 16. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 16. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 10. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • 20261008
  • 32560207 (Muu apuraha/rahoitusnumero: National Natural Science Foundation of China)
  • 2026CXZX-272 (Muu apuraha/rahoitusnumero: Gansu Provincial University Graduate Innovation Star Project)
  • GSJKKY2025-19 (Muu apuraha/rahoitusnumero: Gansu Provincial Disease Prevention and Control Research Program)
  • GSWSQN2025-25 (Muu apuraha/rahoitusnumero: Gansu Provincial Health Research Project)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

Individual participant data will not be shared because the dataset contains sensitive psychiatric and clinical information. The study team has no current plan to make individual-level data available to external researchers.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa